Autophagy and Tau Protein.

Area of Science:

• Neuroscience
• Cell Biology
• Pathology

Background:

• Alzheimer's disease (AD) is characterized by neurofibrillary tangles and senile plaques.
• Autophagic vacuoles accumulate around senile plaques in AD brains, indicating impaired autophagy.
• Tau protein, particularly phosphorylated and truncated forms, is implicated in both AD pathology and autophagy dysfunction.

Purpose of the Study:

• To investigate the impact of autophagy inhibition on tau protein accumulation in a neuronal model of tauopathy.
• To explore the role of the autophagy-lysosome system in the degradation of tau protein.

Main Methods:

• Utilized a neuronal cellular model (M1C cells) expressing wild-type tau (4R0N).
• Administered lysosomotrophic agents (NH4Cl) and autophagy inhibitors (chloroquine, 3-methyladenine) to the cells.
• Assessed the effect of these agents on tau accumulation.

Main Results:

• Chloroquine, NH4Cl, and 3-methyladenine significantly increased tau accumulation in M1C cells.
• These findings demonstrate that disturbances in the autophagy-lysosome system impair tau protein degradation mechanisms.
• Evidence suggests tau protein itself can disrupt autophagy function.

Conclusions:

• Dysfunction of the autophagy-lysosome system is a key factor in the accumulation of tau protein in Alzheimer's disease.
• Modulating autophagy presents a promising therapeutic strategy for Alzheimer's disease.
• Several autophagy modulators have been proposed, including rapamycin, lithium, and metformin.